Shots:
- Datar Cancer Genetics has introduced Exacta AI (multi-analyte platform) to provide ~10 evidence-based drug combinations as a treatment for cancer patients who have exhausted SoC options
- Exacta AI integrates 360° tumor work-up with AI-driven analysis of complex tumor interactome data to assess drug interactions, toxicity, & side effects for ADCs, CPIs, targeted therapies, repurposed drugs, plus endocrine & CT agents.
- Additionally, in a retrospective in-silico study, Exacta AI has generated 7–10 therapy options for 265 pts with drug-resistant solid organ cancers & no SoC option, while standard molecular profiling provided only ~2 options for 15% pts
Ref: PR Newswire | Image: Datar Cancer Genetics
Related News:- Life Spine Receives US FDA’s 510(k) Clearance for ProLift Pivot Expandable Spacer System
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
